<DOC>
	<DOCNO>NCT00611572</DOCNO>
	<brief_summary>This study investigate interaction NMDA ( N-Methyl-D-aspartic acid ) antagonism GABA ( gamma-aminobutyric acid ) system relate cognitive function assess ERPs ( event-related potential ) healthy volunteer .</brief_summary>
	<brief_title>GABA-glutamate Interactions Psychosis</brief_title>
	<detailed_description />
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>Inclusion criterion : Ages 2145 year ethnic background . Male female . Written informed consent . Exclusion criterion : DSMIV diagnosis psychotic , depressive anxiety disorder . A history significant medical/neurological disease cardiac , thyroid , renal , hepatic abnormality , seizure disorder . Unstable medical condition base EKG , vital sign , physical examination laboratory workup ( CBC differential , SMA7 , LFTs , TFTs , UA , Utox ) . History abnormal EEG . History severe allergy multiple adverse drug reaction . Any medication could interfere either safety study and/or outcome measure . Any condition opinion investigator would preclude participation study . History major psychiatric disorder first degree relative . Current substance abuse/dependency determine urine toxicology . Treatment medication CNS effect . Treatment benzodiazepine within one week prior test . Current treatment medication psychotropic effect . Education &lt; 10th grade . IQ &lt; 70 , MR. NonEnglish speaking .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>GABA</keyword>
	<keyword>glutamate</keyword>
	<keyword>NMDA</keyword>
	<keyword>P300</keyword>
	<keyword>MMN</keyword>
</DOC>